GEn1E Lifesciences Adds NextGen Selective Immunomodulator Target to Portfolio, Broadens Pipeline

Tuesday, July 26, 2022

GEn1E plans to use the novel discovery, which is licensed from University of Maryland, Baltimore, to develop therapies for pulmonary, oncology and muscle degenerative diseases BALTIMORE and PALO ALTO, Calif., July 26, 2022 /PRNewswire/ -- GEn1E Lifesciences, a next-generation multitarget techbio... read more